Curasight: Interview with Analyst Fredrik Thor
Redeye recently initiated coverage of Curasight, a Danish biotech company offering a theranostics platform (therapy + diagnostics) in PET imaging and radioligand (local radiation) therapy based on the novel use of the versatile uPAR cancer biomarker. Analyst Fredrik Thor talks us through the investment case.
Sign up for free to continue
Already a member?
Disclosures and disclaimers
Premium Plan required to unlock